SCHEMBL3526404

SCHEMBL3526404

COC(=O)CCC#Cc1cc(Cl)cc(Cl)c1N

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.43
GAA P10253 6/20 0.43
HPGD P15428 4/20 0.43
MAPT P10636 2/20 0.43
HSD17B10 Q99714 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.40
KDM4E B2RXH2 5/20 0.36
GLA P06280 3/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C19 P33261 1/20 0.36
GABRP O00591 1/20 0.35
GABRD O14764 1/20 0.35
GABRA1 P14867 1/20 0.35
GABRB1 P18505 1/20 0.35
GABRG2 P18507 1/20 0.35
GABRB3 P28472 1/20 0.35
GABRA5 P31644 1/20 0.35
GABRA3 P34903 1/20 0.35
GABRA2 P47869 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31487595 0.87 HSD17B10 (0.36) ALDH1A1GAAHPGDMAPTHSD17B10
SCHEMBL3527600 0.81 MAPT (0.43) GAAMAPTL3MBTL1KDM4ECYP1A2
SCHEMBL3526355 0.81 L3MBTL1 (0.38) ALDH1A1GAAMAPTL3MBTL1GABRP
SCHEMBL31487703 0.80 MAPT (0.37) ALDH1A1GAAHPGDMAPTHSD17B10
SCHEMBL3524974 0.79 HDAC3 (0.37) GAAMAPTL3MBTL1GABRPGABRD
SCHEMBL3528298 0.74 MAPT (0.47) ALDH1A1GAAMAPTHSD17B10L3MBTL1
SCHEMBL3527495 0.73 MAPT (0.46) ALDH1A1GAAMAPTHSD17B10L3MBTL1
SCHEMBL16738478 0.72 PGK1 (0.40) ALDH1A1MAPTL3MBTL1GABRPGABRD
SCHEMBL3524537 0.72 ACLY (0.47) HPGDMAPT
SCHEMBL3528411 0.72 L3MBTL1 (0.45) ALDH1A1HPGDMAPTL3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436040-B2 Method of treating conditions involving PPAR-receptors with indole compounds LABORATOIRES FOURNIER S.A. (FR) 2013-05-07 US disclosed
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds LABORATORIES FOURNIER S.A. (FR) 2010-11-11 US disclosed
US-7795297-B2 Indole compounds, method of preparing them and uses thereof LABORATORIES FOURNIER S.A. (FR) 2010-09-14 US disclosed
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LABORATOIRES FOURNIER S.A. (FR) 2008-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LIPG, GPR119, IAPP ALDH1A1 1607/4885GAA 772/4885HPGD 497/4885
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds GPR119, PPARA, PPARG ALDH1A1 1453/4885GAA 1440/4885HPGD 449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.